See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current ...

A new type of PrEP injection, requiring only three injections a year, could be on the way. The FDA approved injections of cabotegravir in 2021 as a form of PrEP, to minimize the risk of acquiring HIV.

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The company revealed its results at this week’s Conference on Retroviruses and ...

A Gilead Sciences drug that protects against HIV infection has won a highly anticipated FDA approval, becoming the first medication for HIV prevention available as a twice-yearly injection. The ...

Wirth is the CEO of Amida Care. Crowley is the director of the O’Neill Institute’s Center for HIV and Infectious Disease Policy at Georgetown Law. In June, a clinical trial showed that a twice-yearly ...

Twice-yearly lenacapavir (Sunlenca) substantially reduced HIV infection when used for preexposure prophylaxis (PrEP) in cisgender men and transgender or gender-nonbinary persons in the pivotal PURPOSE ...

BRISBANE, Australia – When given a choice for pre-exposure prophylaxis (PrEP) to prevent infection with HIV, women preferred injectable cabotegravir (Apretude) every 2 months rather than an oral pill ...

On top of offering various PrEP and PEP medications to students, Student Health expanded its HIV prevention medications this semester with lenacapavir, a twice-per-year injection the Food and Drug ...

By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients ...

(CNN) — A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than the primary option available for pre-exposure prophylaxis or PrEP. ...

Nationwide, an estimated 1.2 million people are eligible to receive medication that can prevent the spread of life-threatening HIV infection. But only roughly a third of those eligible are currently ...